This study will be a 12-week, open-label trial that is designed to evaluate the
Opioid-Sparing effect of Dronabinol at ranging doses when coadministered with the opioid
analgesics that are currently being prescribed to patients for their chronic pain condition.
The purpose of this trial will be to assess the effectiveness of Dronabinol when combined
with opioid analgesics to relieve pain at lower opioid doses and to evaluate any reduction of
opioid-related side effects. Participants will take the study-drug, Dronabinol, along with
their regular prescribed opioids and the results will be evaluated and analyzed according to
defined endpoints.